Elotuzumab (Empliciti) — CPB 0899 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0899 covering elotuzumab (Empliciti) billing, effective March 3, 2026. Here's what billing teams need to know about the current coverage criteria.

Aetna's elotuzumab coverage policy under CPB 0899, effective March 3, 2026, covers elotuzumab for multiple myeloma as well as POEMS syndrome, plasma cell-related MIDD, and plasma cell-related MGRS. The primary billing code affected is J9176 (injection, elotuzumab, 1 mg), along with combination agent codes J9041, J9046, J9047, J9048, J9049, J9051, J9054, J1100, J8540, and J8541. If your hematology oncology or specialty infusion practice bills elotuzumab for Aetna commercial members, this policy determines which diagnoses support medical necessity—and therefore which prior authorization requests will clear.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Elotuzumab (Empliciti) — CPB 0899
Policy Code	CPB 0899
Change Type	Modified
Effective Date	March 3, 2026
Impact Level	High
Specialties Affected	Hematology/Oncology, Specialty Infusion, Oncology Pharmacy
Key Action	Update your prior auth workflows and ICD-10 mapping to include POEMS, MIDD, and MGRS diagnoses before submitting new elotuzumab requests

---

Aetna Elotuzumab Coverage Criteria and Medical Necessity Requirements 2026

The core of this coverage policy is combination therapy. Aetna does not cover elotuzumab (J9176) as a single agent. Every path to medical necessity approval runs through one of three approved regimens.

Regimen 1: Elotuzumab with lenalidomide and dexamethasone (J1100, J8540, or J8541 for dexamethasone).

Regimen 2: Elotuzumab with bortezomib (J9041, J9046, J9048, J9049, J9051, or J9054) and dexamethasone.

Regimen 3: Elotuzumab with pomalidomide and dexamethasone — but only for members who have received at least two prior therapies. Those prior therapies must include both an immunomodulatory agent and a proteasome inhibitor.

That third regimen is where prior authorization requests most often go sideways. If your documentation doesn't explicitly confirm the two prior therapy lines — with both agent classes named — expect a denial. Build that documentation requirement into your precertification checklist now.

Prior Authorization Requirements

Precertification is required for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax a Statement of Medical Necessity (SMN) form to (888) 267-3277. Don't skip this step on the assumption that an established patient's authorization carries forward — reauthorization requires its own documentation showing no unacceptable toxicity and no disease progression.

Expanded Indications Under Current Policy

The current policy explicitly covers elotuzumab for three plasma cell disorder diagnoses beyond multiple myeloma: POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes), plasma cell-related Monoclonal Immunoglobulin Deposition Disease (MIDD), and plasma cell-related Monoclonal Gammopathy of Renal Significance (MGRS).

These are rare plasma cell disorders. But if your practice sees hematology patients, you likely have at least a handful of these cases. The current CPB 0899 policy establishes a defined coverage path for POEMS, MIDD, and MGRS — provided the same combination therapy criteria apply as for multiple myeloma.

The real issue here is ICD-10 mapping. Your charge capture team needs to know which codes support these diagnoses, because Aetna's code list for this policy runs deep. The effective date is March 3, 2026 — if you're already treating these patients, don't wait.

---

Aetna Elotuzumab Exclusions and Non-Covered Indications

Aetna's position is plain: any indication not listed in the initial approval criteria is experimental, investigational, or unproven.

That means elotuzumab monotherapy is not covered. It also means any combination regimen not on the approved list — say, elotuzumab paired with daratumumab or a novel agent in a clinical trial — won't clear medical necessity review under commercial policy.

Watch for off-label requests that don't match one of the three approved regimens. If your oncologists are using elotuzumab in a non-standard combination based on emerging data, prior authorization under CPB 0899 won't support it. Those cases may need a peer-to-peer review or a formal appeal with clinical literature. Loop in your compliance officer before submitting requests that don't fit the criteria exactly.

---

Coverage Indications at a Glance

---

Aetna Elotuzumab Billing Guidelines and Action Items 2026

These aren't general reminders. These are the specific gaps this policy creates for your billing team.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Elotuzumab Under CPB 0899

HCPCS Codes Covered When Selection Criteria Are Met

Note on J9047: Carfilzomib appears in the code table but is not part of any approved elotuzumab combination regimen described in the criteria. Don't assume its presence here means elotuzumab + carfilzomib combinations are covered. The criteria are explicit — only the three listed regimens qualify. If your practice is considering a carfilzomib-based combination, talk to your compliance officer before billing.

Key ICD-10-CM Diagnosis Codes

The full ICD-10 list under CPB 0899 contains 159 codes. Below are the codes listed in the policy data. Map these against your active elotuzumab patients before March 3, 2026.

The full 159-code set — including the specific myeloma, POEMS, MIDD, and MGRS codes — is available in the source policy. Pull the complete list from the CPB 0899 Aetna policy document and load it into your EHR's diagnosis crosswalk. Don't rely on this summary for your final code mapping.

---